Recipient e-mail address

Your e-mail address
MENU

transformative-opportunities

From formulation challenges to proprietary product solutions

Taste Masking and ODTsTaste Masking and ODTsCustomized Drug ReleaseCustomized Drug ReleaseBioavailability EnhancementBioavailability Enhancement

Taste Masking and ODTs

Technologies to improve taste and provide alternative dosage forms

Microcaps®AdvaTab®Liquitard®

Customized Drug Release

Technologies to optimize therapeutic performance

Diffucaps®Eurand Minitabs®Diffutab®Orbexa™

Bioavailability Enhancement

Technologies to improve solubility

Biorise™Diffucaps®

Products for Out-Licensing

Since 2009, our partners have commercialized more than 40 products worldwide.
Learn More

On April 1, 2015,
Aptalis Pharmaceutical Technologies
was divested from Actavis plc (NYSE: ACT)
to TPG, a global private investment firm.
The company’s new name is
 
Adare Pharmaceuticals

For more information on Adare Pharmaceuticals,
you can view the company’s fact sheet here.

×